Business Context and Reporting Period
This Form 8-K is filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on June 8, 2018, with a signature date of June 13, 2018. The filing reports a corporate restructuring plan, a strategic review for potential sale or merger, and the termination of specific clinical trials.
Key Financial Metrics and Costs
The filing does not provide revenue, profit, cash flow, or margin data. Key financial figures relate to restructuring costs:
- Estimated One-Time Restructuring Costs: $0.8 million to $1.1 million (primarily termination benefits).
- Executive Separation Payment: $257,250 lump sum (nine months' base salary) for the departing Chief Medical Officer.
- Expected Cost Savings: Annualized savings expected to begin in the third quarter of 2018 following a ~60% workforce reduction.
Material Changes
- Workforce Reduction: The Board approved a plan to reduce the workforce by approximately 60%, with the majority of reductions expected by June 30, 2018.
- Strategic Review: The Company initiated a process to explore strategic alternatives, including a potential sale or merger, engaging Wedbush PacGrow as a financial advisor.
- Clinical Trial Termination: On June 13, 2018, the Company announced the end of Phase 2 trials for FLX-787 in amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease due to oral tolerability concerns.
- Leadership Change: Dr. Thomas Wessel transitioned from Chief Medical Officer to an outside advisor effective June 26, 2018.
Outlook, Risks, and Management Commentary
Management intends to focus the reduced internal team on assessing FLX-787 for dysphagia (difficulty swallowing) and operating the HOTSHOT consumer business. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations. There is no assurance that the strategic review will result in a transaction.
Investor Verification Checklist
- Verify the exact number of employees remaining after the 60% reduction.
- Confirm the timeline and status of the strategic review process and any potential transaction.
- Review the specific clinical data regarding oral tolerability concerns for FLX-787.
- Monitor future filings for amendments regarding additional exit costs or charges.
- Check the upcoming Form 10-Q for the full text of the Advisor and Separation Agreements.